| Literature DB >> 27847602 |
Rohan Merani1, Alex P Hunyor2.
Abstract
The purpose of this review is to report and summarize previously reported studies and assess many of the individual steps of the intravitreal injection procedure's possible effect on the prevention of endophthalmitis. The pooled endophthalmitis rate from 20 large retrospective case series of anti-VEGF injections was 144/510,396 (0.028%; 1/3,544). Injections may be performed in an office-based location or in an operating room (OR) and low rates of endophthalmitis can be achieved in either location with careful attention to asepsis. Pre- or post-injection topical antibiotics have not been shown to be effective, and could select for more virulent microorganisms. Povidone-iodine prior to injection is accepted as the gold-standard antiseptic agent, but aqueous chlorhexidine may be an alternative. Antisepsis before and after gel or subconjunctival anesthetic is suggested. The preponderance of Streptococcal infections after intravitreal injection is discussed, including the possible role of aerosolization, which can be minimized by using face masks or maintaining silence. As with other invasive procedures in medicine, the use of sterile gloves, following adequate hand antisepsis, may be considered. Control of the eyelashes and lid margin is required to avoid contamination of the needle, but this can be achieved with or without a speculum. Techniques to minimize vitreous reflux have not been shown to reduce the risk of endophthalmitis. Same day bilateral injections should be performed as two separate procedures, preferably using drug from different lots, especially when using compounded drugs.Entities:
Keywords: Anti-VEGF; Antibiotics; Antisepsis; Chlorhexidine; Endophthalmitis; Intravitreal injection; Masks; Povidone-Iodine; Speculum; Streptococcus
Year: 2015 PMID: 27847602 PMCID: PMC5088471 DOI: 10.1186/s40942-015-0010-y
Source DB: PubMed Journal: Int J Retina Vitreous ISSN: 2056-9920
Endophthalmitis following intravitreal anti-VEGF injection—retrospective cases series with at least 10,000 injection
| Period and location | Authors | n = injections | Rate of clinically suspected IE | Pre-injection antibiotics | Post injection antibiotics | Mask | Drape | Conjunctival povidone-iodine concentration | Anaesthetic agents used | Sterile lid speculum | Gloves | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Jan 2009 to 1 Oct 2012 | Storey et al. [ | 117,171 |
| Variable | Variable | No* | No | 5% | Drops | Variable | Nil* | Office |
| 1 Jan 2005 to 31 Dec 2010 | Moshfeghi et al. [ | 60,322 |
| No | Variable | No* | No | 5% | Drops | Yes | Non-sterile | Office |
| 1 Jan 2007 to 31 Dec 2011 | Chaudhary et al. [ | 49,002 |
| Yes | Yes | No | No | 5% | Drops | Yes | Nil or non-sterile | Office |
| 2004 to 2012 | Casparis et al. [ | 40,011 |
| No | Variable (yes in one hospital, no in the other) | Yes | Yes (adhesive) | 5–10% | Drops | Yes | Sterile | OR |
| 1 Aug 2006 to 31 Jul 2007 | Klein et al. [ | 30,736 |
| Variable | ? | ? | ? | 5–10% | ? | Variable: used in 14 of the 15 cases with endophthalmitis | ? | Office |
| July 2000 to July 2010 | Chen et al. [ | 29,995 |
| Yes | Yes | No* | No* | 5–10% | Drops | Yes | Non-sterile* | Office |
| 1 Jun 2005 to 7 Aug 2007 | Fintak et al. [ | 26,905 |
| No* | Variable (used in all the cases of endophthalmitis) | No* | No* | 5–10% | Drops | Variable (used in all the cases of endophthalmitis) | Nil* | Office |
| March 2007 to May 2013 | Brynskov et al. [ | 20,293 |
| No | Variable | Yes | Yes (adhesive) | 5% | Drops | Yes | Sterile | OR |
| 1 Aug 1997 to | Bhavsar and Sandler [ | 17,666 |
| No | No | No | No | 5% (before and after injection) | Drops | Yes | Non-sterile | Office |
| Jan 2005 to end July 2012 | Nentwich et al. [ | 18,202 |
| No | Yes | Yes | Yes (non-adhesive)* | 1% | Drops | Yes | Sterile | OR |
| Jan 2007 to May 2012 | Mithal et al. [ | 15,925 |
| No* | Yes* | Yes* | Variable | 2.5%* | Drops* | Yes* | Sterile* | Office* |
| July 2009 to July 2012 | Shimada et al. [ | 15,144 |
| Yes | Yes | Yes | Yes (adhesive) | 0.25% (before and after injection) | Drops + Subconj | Yes | Yes | Office |
| Jan 2005 to Aug 2010 | Cheung et al. [ | 14,960 |
| Variable | Variable | No* | No | 10% | Drops | Yes | Nil* | Office |
| Mar 2006 to Mar 2012 | Abell et al. [ | 12,249 |
| No | Variable (used until 2011)* | Yes | Yes (non-adhesive)* | 10% | Drops + Gel* | Yes | Sterile | Office = 4/3,376 |
| Jan 2009 to Dec 2011 | Tabandeh et al. [ | 11,257 |
| Yes in OR | Yes | Yes in OR | Yes in OR | 5% | Drops | Yes | Sterile in OR | Office = 3/8,647 |
| 5 Jan 2005 to 18 Oct 2007 | Pilli et al. [ | 10,254 |
| No | Yes | No | No | 5% | Drops | Variable | ? “Surgical attire was not used” | Office |
| Nov 2010 to Dec 2011 | Fineman et al. [ | 10,164 |
| No* | Variable (used until Oct 2,011) | No* | No* | 5% | Drops | No | Nil or non-sterile* | Office* |
| 1 Jan 2007 to 31 Dec 2011 | Englander et al. [ | 10,140 |
| Variable* | Variable | Variable* | Variable | Yes, 5% | Drops | Variable | Variable* | Office* |
Steroid and other injections have been excluded.
Anesthetic: “Drops” refers to drops given alone or with the aid of a cotton bud or pledget.
Location: “office-based” includes studies where the injections were performed in a clean procedure room, or in the consulting room itself, within an office or outpatients department.
Rani ranibizumab, Bev bevacizumab, Aflib aflibercept and Peg pegaptanib.
* These points were not explicitly mentioned in the manuscript, but were clarified through personal communication with the corresponding author of the paper.
? These points were not mentioned in the manuscript, and the corresponding authors could not be contacted.